Paris & New York, April 9, 2018
- Separation of the functions of Chairman and CEO
- Reappointment of Lionel Ségard as Chairman of the Board of Directors
- Appointment of Jean-Philippe Milon as CEO
Quantum Genomics (Euronext Growth – FR0011648971 – ALQGC), a biopharmaceutical company specialising in the development of a new class of drugs directly acting on the brain to treat unmet medical needs in the field of cardiovascular diseases, is strengthening its governance by separating the functions of Chairman and CEO. This reorganisation should allow Quantum Genomics to meet its two primary objectives: intensifying its research activities and achieving its market potential.
To this end, Lionel Ségard is reappointed as Chairman of the Board of Directors, and Jean-Philippe Milon is named CEO. Lionel Ségard, co-founder of Quantum Genomics, will continue to participate in the company's development through his strategic vision and his experience. The Scientific Advisory Board will continue to report to him and he will also remain one of the major shareholders of Quantum Genomics. Jean-Philippe Milon will now ensure the executive management of the company, for which he served as part-time Chief Operating Officer since June 2013. Before joining Quantum Genomics, Jean-Philippe Milon, Doctor in Pharmacy, served notably as Chairman of the Executive Board of Bayer France, a pharmaceutical group that works closely in the field of cardiovascular diseases, and a member of the international executive committee of Bayer Healthcare in charge of mergers and acquisitions, licensing and business development.
Lionel Ségard stated: “Jean-Philippe's experience in the pharmaceutical industry, and particularly in the field of cardiovascular diseases, is a precious asset at a time when we are undertaking new stages of development. I am therefore very happy to pass him the baton on operational matters, and to continue to work alongside him to realise the sales potential of our drug candidates. Moreover, the separation of the functions of Chairman and CEO is in line with best practices in terms of corporate governance and a sign of maturity for Quantum Genomics. "
For his part, Jean-Philippe Milon wished to “thank the Board of Directors for the trust it has placed in me. I am thrilled to be committing myself 100%, and alongside Lionel, to the development of Quantum Genomics which has all the necessary assets to become a leading player in the field of cardiovascular diseases. As our development programmes continue, we will have to intensify our discussions with pharmaceutical groups, with the aim of signing a partnership in the next 24 months in order to ensure the market launch of our new class of therapeutic drugs, a major source of hope for millions of patients around the world. "
These nominations take place as the company is preparing to unveil its three-year strategic plan on April 19.
A complementary duo to guide Quantum Genomics through the next stages of its development
Lionel Ségard, a biochemist by training, served as CEO of Inserm-Transfert, the subsidiary of INSERM in charge of technological transfer, from its creation until 2006. He is also the founder and former president of the company Inserm Transfert Initiative, an investment company specialising in the healthcare field, and participated in the seed funding and financing of innovative companies such as Innate Pharma, Immupharma and TX Cell. In addition, Lionel Ségard is one of the founders of the Strategic Council for Innovation (Secretary General from 2003 to 2005).
Jean-Philippe Milon is a Doctor in Pharmacy and holds an MBA from ESCP. He began his career in 1985 at Yamanouchi Pharmaceutical (now Astellas) before holding a variety of positions in sales and marketing within several large pharmaceutical groups, notably Sandoz, where he was head of marketing for the cardiology, asthma and bone and mineral metabolism departments. He then became Managing Director of the biotechnology company Centocor for France, Belgium and Switzerland. In 1993, he joined Bayer Pharma France as Head of Sales and Marketing, before becoming Managing Director of the Group in Benelux. Named Chairman of the Executive Board of Bayer Healthcare France in 2003, he later became Senior Vice President of Worldwide Strategic Marketing and a member of the Worldwide Executive Committee of Bayer Healthcare in charge of business development and mergers and acquisitions. Since 2013, he has served part-time as Chief Operating Officer of Quantum Genomics.
16-17 April 2018 SmallCap Event (Paris)
19 April 2018 Announcement of three-year strategic plan
To comment on these strategic decisions, Quantum Genomics will organise a phone conference in English on Thursday 19 April at 6.00 pm Paris time (12:00 Eastern time):
About Quantum Genomics
Quantum Genomics is a biopharmaceutical company that specialises in the development of a new class of cardiovascular medications based on brain aminopeptidase A inhibition (BAPAI). Quantum Genomics is the only company in the world exploring this innovative approach that directly targets the brain. The company relies on its 20-plus years of basic and clinical research at some of the largest French laboratories: the French National Institute of Health and Medical Research (INSERM), the French National Centre for Scientific Research (CNRS), the Collège de France, and Paris-Descartes University. The goal of Quantum Genomics is to develop innovative treatments for complicated, or even resistant, cases of hypertension (around 30% of patients have poor control of their condition or receive ineffective treatment) and for heart failure (one in two patients diagnosed with heart failure dies within five years).
Based in Paris and New York, the company is listed on the Euronext Growth exchange in Paris (FR0011648971—ALQGC) and trades on the OTCQX market in the United States (symbol: QNNTF). Click here for more information about Quantum Genomics. Follow us on Twitter and LinkedIn.
Chairman and CEO
+33 (0)1 85 34 77 70
+33 (0)1 85 34 77 70 | email@example.com
Media Relations and Scientific Communications
+33 (0)6 88 48 48 02 | firstname.lastname@example.org
+33 (0)6 85 82 41 95 | email@example.com
|Edison Advisors (U.S.)
+1 (646) 653-7035 | firstname.lastname@example.org